Gemcabene 900 mg
Drug3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
NCT Number: NCT02587390
The purpose of this study is to determine the effect of gemcabene on the pharmacokinetics of simvastatin 80 mg.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Time frame: 15 days
Cmax
Time frame: 15 days
Area Under the Curve (AUC)
Time frame: 57 days
Time frame: 57 days
Clinical Laboratory Abnormalities
Time frame: 57 days
Clinically Significant Changes
NeuroBo Pharmaceuticals Inc.
Industry
A Study to Evaluate the Effects of Gemcabene on the Steady-State Pharmacokinetics and Pharmacodynamics of Simvastatin in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07737067
Arthrosclerosis, Dyslipidemias
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05694260
Dyslipidemias, Hypercholesterolemia
Los Angeles, California, United States
View Trial DetailsNCT07655960
Dyslipidemia, Dyslipidemias
Seoul, South Korea
View Trial DetailsNCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial Details